BioCryst re­sumes en­roll­ment for im­mune dis­eases drug; Ea­gle buys stake in res­pi­ra­to­ry dis­ease biotech

In April, the FDA hit BioCryst with a par­tial hold, lead­ing the biotech to pause en­roll­ment on three of its rare dis­ease clin­i­cal tri­als and send­ing its shares down 30%.

Last week, BioCryst said the par­tial clin­i­cal hold had been re­solved and that it would re­sume en­rolling its clin­i­cal tri­als for its drug, dubbed BCX9930, but with new pro­to­cols at a low­er 400 mg dose.

BioCryst’s drug is a fac­tor D in­hibitor, which was be­ing test­ed in an ar­ray of im­mune dis­eases. The biotech is run­ning two piv­otal tri­als for parox­ys­mal noc­tur­nal he­mo­glo­bin­uria, as well as a third tri­al look­ing at a set of three dis­eases — C3 glomeru­lopa­thy, IgA nephropa­thy and pri­ma­ry mem­bra­nous nephropa­thy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER